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Key points 1 
1. Humanized niche xenograft mouse models were generated that enable engraftment of leukemia 2 
patient cells covering all risk groups 3 
2. Self-renewal is better maintained in the humanized niches as determined by serial 4 
transplantation and genome-wide transcriptome studies 5 
  6 
 4 
 
 1 
Abstract 2 
 3 
In order to begin to understand mechanisms that regulate self-renewal, differentiation and 4 
transformation of human hematopoietic stem cells, or to evaluate the efficacy of novel treatment 5 
modalities, stem cells need to be studied in their own species-specific microenvironment. By 6 
implanting ceramic scaffolds coated with human mesenchymal stromal cells (MSCs) into immune 7 
deficient mice we mimic the human bone marrow niche. Thus, we have established a human 8 
leukemia xenograft mouse model in which a large cohort of patient samples successfully engrafted 9 
covering all important genetic and risk subgroups. We find that by providing a humanized 10 
environment stem cell self-renewal properties are better maintained as determined by serial 11 
transplantation assays and genome-wide transcriptome studies, and less clonal drift is observed as 12 
determined by exome sequencing. The human leukemia xenograft mouse models that we have 13 
established here will serve as an excellent resource for future studies aimed at exploring novel 14 
therapeutic approaches. 15 
 16 
 17 
 18 
  19 
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Introduction  1 
In order to study the molecular mechanisms involved in human leukemias and to improve 2 
treatment options, establishing in vivo xenograft models that faithfully recapitulate the disease is 3 
essential. Currently, NOD-SCID IL2R-/- (NSG) xenograft models are considered to be the gold 4 
standard for evaluating engraftment of human haematological malignancies. However, this model 5 
has serious drawbacks since 30-40% of primary AML samples fail to engraft even in this most 6 
immune-compromised NSG model.
1-3
 In addition, engraftment of normal human CD34
+
 cells in 7 
NSG mice is lymphoid biased and in vivo myeloid transformation has been much more difficult to 8 
achieve in NOD-SCID based xenograft models, including the NSG mice.
4-8
 Furthermore, using 9 
retro/lentiviral systems to model human leukemias we frequently observe that while in vitro both 10 
myeloid and lymphoid transformation can be achieved upon expression of oncogenes such as 11 
MLL-AF9 or BCR-ABL/BMI1, in vivo transformation in mice is strongly biased towards ALL.
5,6
 12 
This is in contrast to patients expressing the BCR-ABL p210 oncoprotein, which can give rise to 13 
both myeloid and lymphoid leukemias, and the same is true for MLL-AF9 in paediatric leukemia 14 
patients. Together, these observations suggest that a specific human microenvironment might be 15 
necessary for engraftment and maintenance of self-renewal of myeloid leukemic stem cells.  16 
Since certain myeloid growth factors are often species-specific, the murine bone marrow niche is 17 
most likely not sufficient to provide the appropriate environment for human LSCs. NOD/SCID-18 
3/GM/SF mice engineered to produce human IL3, GM-CSF and Steel Factor/SCF
9-11
 and NOD-19 
SCID IL2R-/- (NSG) mice expressing human IL3, GM-CSF and SCF (NS-SGM3)3 have been 20 
generated, and enhanced engraftability of primary human AML samples was observed in these 21 
mouse strains. Also, the expression of these three human growth factors was sufficient to allow 22 
AML development upon transplantation of CB CD34
+
 cells expressing MLL-AF9.
3
 Various other 23 
 6 
 
mouse strains have also been developed
11-17
 including MISTRG mice expressing M-CSF, IL3, 1 
GM-CSF, TPO and SIRP12 and are therefore useful tools, although other human niche-specific 2 
factors might still be missing. 3 
To develop in vivo mouse leukemia xenograft models that would more faithfully recapitulate 4 
human leukemias we made use of a humanized niche xenograft model in which ceramic scaffolds 5 
coated with human mesenchymal stromal cells (MSCs) used to mimic the bone marrow 6 
microenvironment are implanted in immunodeficient  mice.
18,19
 Next we studied the engraftment of 7 
a large cohort of primary AML patient samples covering all important genetic and risk subgroups. 8 
Our data indicate that the presence of a humanized microenvironment favors engraftment of AML 9 
patient samples, including favorable risk AML samples that are notoriously difficult to engraft in 10 
NSG strains and that self-renewal is better maintained in the human niche. 11 
 12 
Methods 13 
Establishment of the humanized scaffold niche xenograft model and transplantations 14 
The ectopic bone model was established as described previously.
18,19
 Briefly, four to six hybrid 15 
scaffolds consisting of three 2–3mm biphasic calcium phosphate (BCP) particles loaded with 16 
human MSCs were implanted subcutaneously into female NOD.C-Prkdcscid Il2rtm1Wjl/SzJ 17 
(NSG) or RAG2
-/-c-/- mice. Eight weeks after scaffold implantation, different cell doses ranging 18 
from 5x10
4
 to 4x10
6
 were directly injected into the scaffolds as indicated during primary as well as 19 
secondary transplantations. 20 
 21 
Patient samples  22 
 7 
 
Peripheral blood and bone marrow from untreated patients diagnosed with AML/ BC-CML/ B-1 
ALL at the UMCG or VUmc were studied after informed consent and protocol approval by the 2 
Medical Ethical Committee of the UMCG or VUmc, in accordance with the Declaration of 3 
Helsinki. After ficoll separation of mononuclear cells, cells were cryopreserved until further use. 4 
CD34
+
 cells were enriched or CD3
+
 cells were depleted using a magnetically activated cell-sorting 5 
CD34 progenitor kit or automatically by using auto Macs (Miltenyi Biotech) as described 6 
previously.
6,20
 7 
 8 
Additional Methods are described in the Supplemental Materials 9 
 10 
Results 11 
 12 
Establishing xenograft human leukemia models using three-dimensional scaffolds coated 13 
with human MSCs. 14 
A cohort of 39 patients was selected to establish humanized niche mouse xenograft leukemia 15 
models (Supplemental Table 1; 17/39 (44%) adverse risk group, 8/39 (21%) intermediate risk and 16 
14/39 (36%) favorable risk). Cells were injected into a humanized model that is based on 17 
subcutaneous implantation of human BM-like scaffolds (huBM-sc) in order to provide a human 18 
microenvironment, as described previously.
18,19
 Briefly, in this model ceramic scaffolds coated 19 
with human mesenchymal stromal cells (MSCs) were implanted subcutaneous in immunodeficient 20 
mice where they developed into structures mimicking a human bone marrow microenvironment 21 
including bone formation, and ossicles were vascularized by murine blood vessels (Figure 1B, 22 
Supplemental Figure 1, Supplemental Figure 2A). Six to eight weeks later, CD34
+
 or CD3
+
-23 
 8 
 
depleted AML mononuclear cells (MNCs) were then injected in these so-formed “ossicles”. As 1 
comparator, 6 of the patient samples were also injected intravenously (i.v., referred to as muBM-iv) 2 
in mice without human scaffolds to evaluate engraftment in a murine microenvironment (Figure 3 
1A, Supplemental Table 1). As second comparator, cells were injected either directly in the 4 
scaffold or i.v. in mice that did carry humanized scaffolds in 5 selected cases (referred to as IV 5 
huBM-sc, Figure 1A, Figure 1E). Experiments were carried out independently in two institutes 6 
using 2 different mouse strains, NSG (at the UMCG, NL) and Rag2
-/-c-/- mice (at the VU, NL) 7 
(Supplemental Table 1) showing robustness of the model. Leukemic cell engraftment was 8 
monitored over time with PB sampling and/or by monitoring tumor volume in the scaffolds (Figure 9 
1A, Supplemental Table 2). Hematoxylin and Eosin (HE) staining of non-injected scaffold sections 10 
6 weeks after implantation confirmed the presence of extramedullary bone in the scaffolds. 11 
Different magnifications reveal the presence of stromal cells and bone material deposited in the 12 
cavities of the ceramic particle, and blood vessels of mouse origin were also observed (Figure 1B, 13 
Supplemental Figure 1A, Supplemental Figure 2A). 14 
For huBM-sc mice, chimerism levels in the PB were usually low (Supplemental Table 2), so the 15 
volume of the biggest tumor growing on one of the scaffolds at approximately 1.5-2 cm
3
 was 16 
defined as endpoint of the experiment. MuBM-iv mice were terminated when we observed 17 
huCD45
+ 
levels in the PB around 30-60% of total living cells together with signs of illness. We 18 
obtained engraftment and outgrowth of leukemic cells in 3 out of 7 cases with the muBM-iv model 19 
(43%) and in 29 out of 39 cases (74%) in the huBM-sc model. Lack of engraftment was not due to 20 
an absence of bone formation in the scaffolds (Supplemental Figure 1B). Notably, favorable risk 21 
leukemias only engrafted in the huBM-sc model but no engraftment was observed in any of the 22 
muBM-iv mice without humanized scaffolds, and the same was true for patient sample #2 that also 23 
 9 
 
did not engraft in the muBM-iv model (Figure 1C, Supplemental Table 1). All 7 favorable risk 1 
AMLs with an inv16, which are notoriously difficult to engraft in NSG mice, efficiently engrafted 2 
in the huBM-sc mice (Supplemental Table 1). AML #1  engrafted in both the huBM-sc as well the 3 
muBM-iv models with similar kinetics of leukemia development, while AMLs #3 and #4 did 4 
engraft in the muBM-iv model but with slower kinetics as compared to the huBM-sc model 5 
(Supplemental Table 2). 6 
All intermediate risk samples engrafted in both models (Figure 1C, Figure 1D). Interestingly, in 7 
huBM-sc mice leukemic cells engrafted not only in the humanized scaffold niches but also seeded 8 
into murine hematopoietic organs, with engraftment levels in murine compartments increasing 9 
concomitantly with prognosis of disease (e.g. the percentage of human leukocytes in muBM ranged 10 
from 4 to 20% in the favorable risk mice while chimerism levels in murine BM, spleen and liver 11 
were significantly higher in mice injected with adverse risk samples reaching up to an average of 12 
55% in one case of adverse risk leukemia) (Figure 1D). Five AML samples were i.v. injected in 13 
mice carrying humanized scaffolds (Figure 1A, route 3). All samples efficiently seeded into the 14 
scaffolds while only in 2/5 cases engraftment was also observed in the human bone marrow (Figure 15 
1E). 16 
The onset of tumor initiation and consequently the time of sacrifice (14-38 weeks) were variable 17 
from patient to patient, with tumor growth rates that appeared to correlate with risk group. In the 18 
majority of animals, tumors be palpable 100 days after injection with the exception of 2 cases of 19 
adverse risk AML (#4 and #2) where the onset was earlier than 100 days (Figure 1F, Supplemental 20 
Table 2). Furthermore, using a luciferase gene-marked AML sample, we observed that growth was 21 
initiated 50 days after engraftment (Supplemental Figure 2C). In all cases of engrafted intermediate 22 
 10 
 
and adverse risk leukemias, the growth rate (read out by the slope of the curve) was faster than in 1 
favorable risk AMLs (Figure 1F, Supplemental Table 2). 2 
 3 
Leukemic cells engrafted in huBM-sc mouse models recapitulate the original phenotype of 4 
the patient. 5 
FACS analysis was performed to compare the immunophenotype of the leukemic cells of the 6 
original patient samples with tumor cells isolated from the human scaffold niche as well as from 7 
the murine compartments. In some cases the original patient immunophenotype was well 8 
conserved in vivo regardless of whether the cells expanded in a humanized or murine 9 
microenvironment, while in other cases the original patient immunophenotype was clearly better 10 
preserved in the humanized scaffolds. An example of the latter is AML #2. This sample contained 11 
an inv16 and a t(9;22) BCR-ABL translocation with no mutations in NPM or FLT3. At 12 
presentation, this patient displayed a relatively large immature population of blast cells (34% 13 
CD34
+
, 48% CD117
+
 CD15
- 
) and all MNCs were positive for CD33 and CD13, weakly positive 14 
for CD14, CD11b, CD11c and CD15, and negative for CD19 (Figure 2A). CD34
+
 blast cells were 15 
isolated from this patient and injected in the scaffolds of NSG mice and within 14 weeks tumors 16 
developed on the scaffolds and the animals were terminated (Figure 2B, Supplemental Table 2). 17 
Scaffold tumors were greenish in color (indicating the presence of myeloid myeloperoxidase 18 
expressing cells) and were well vascularized with murine blood vessels. Leukemic cells could also 19 
be retrieved from murine BM, spleen, liver and PB (Supplemental Table 2). Cells retrieved from 20 
the humanized scaffolds were huCD45
+
 with percentages of CD34
+
 and CD117
+
 comparable to the 21 
percentages at diagnosis, whereas in cells retrieved from BM the percentage of CD34
+
 and in 22 
particular CD117
+
 cells was partially reduced while CD15 and to some extent also CD11b and 23 
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CD14 percentages were increased (Figure 2C, Figure 2D). Histological analysis using HE staining 1 
confirmed that scaffold tumors contained bone and huCD45
neg
 stromal cells surrounded by 2 
huCD45 and huCD33-positive AML blasts (Figure 2E). MGG staining of cytospins confirmed that 3 
scaffold tumors mainly contained immature blast-like cells with big nuclei and BM samples 4 
revealed a more abundant presence of smaller cells with a more differentiated morphology (Figure 5 
2F).  6 
In the case of AML #1, the humanized niche did not clearly confer an advantage to preserve a more 7 
immature phenotype compared to the murine stromal environment (Supplemental Figure 3). This 8 
sample contained a FLT3-ITD, was NPMwt and contained several chromosomal abnormalities 9 
including a t(3;5) NPM-MLF1 translocation, with a high percentage of CD34
+
/CD117
+
 blasts 10 
(Supplemental  Figure 3A). Within 100-150 days tumors were visible and again infiltration of 11 
human CD45
+
 cells was observed in mouse organs as well (Supplemental Figure 3B-C, 12 
Supplemental Table 2). However, the immunophenotype of the original patient sample #1 was now 13 
conserved in both the humanized niche as well as in mouse niches (Supplemental Figure 3C-F). 14 
 15 
Leukemic cells isolated from humanized scaffolds have superior 2
nd
 transplantation capacity 16 
compared to leukemic cells isolated from the murine bone marrow niche. 17 
Secondary transplantation assays were performed for three cases using various doses ranging from 18 
4.5x10
4
-3x10
6
 cells harvested from scaffolds or bone marrow that were injected into individual 19 
scaffolds of secondary mice (Figure 3A). Secondary engraftment transplantation into 2
nd
 scaffolds 20 
could readily be established for huBM-sc-harvested cells in all investigated cases (Figure 3A-G 21 
and Supplemental Figure 2D). For AML #2 secondary transplantation could readily be established 22 
for huBM-sc-harvested cells with 3x10
6
, 1x10
6
 and even 4x10
5
 cells, but no 2
nd
 engraftment was 23 
 12 
 
observed for muBM-iv-harvested cells using up to 4x10
5
 cells (Figure 3B-C, Supplemental Table 1 
2). The same was true for AML #3 whereby 2
nd
 engraftment was observed with 1.5x10
6
 and 1x10
5
 2 
injected huBM-sc-harvested cells, but not with up to 4x10
5
 muBM-iv-harvested cells  (Figure 3D-3 
E, Supplemental Table 2). For AML #1, 2
nd
 engraftment could be established with as little as 4 
4.5x10
4
 huBM-sc-harvested cells, which was not seen with muBM-iv-harvested cells when 5 
injected at the same dose, but injection of 1.8x10
5
 muBM-iv-harvested cells did allow secondary 6 
transplantation, albeit with slower kinetics as compared to huBM-sc-harvested cells at the same 7 
dose (Figure 3F-G, Supplemental Table 2). These data appeared to be in line with flow cytometry 8 
analyses on stem/progenitor compartments suggesting that the immature CD34
+
/CD38
-
 9 
compartments were better preserved in the human niches (Supplemental Figure 4A). Together, 10 
these data again pinpoint to the notion that stemness was better preserved in the humanized niche 11 
for most leukemias, whereby AML #1 seemed to be the least dependent on a human 12 
microenvironment within the tested cohort, in line with our observation that this patient sample 13 
was also able to engraft in the muBM-iv model, while e.g. AML #2 appeared to be much more 14 
dependent on cues from a human microenvironment. We also analyzed lymphoid engraftment, but 15 
did not find any CD3
+
/CD4
+
 or CD3
+
/CD8
+
 cells (Supplemental Figure 4B). 16 
Next, we compared engraftment of a favorable risk, intermediate risk and adverse risk sample in 17 
mice carrying scaffolds coated with either human MSCs or murine MSCs and performed primary 18 
and secondary engraftment experiments (Figure 4A). The adverse risk sample engrafted in both 19 
conditions, regardless of whether scaffolds were coated with human or murine MSCs (Figure 4B). 20 
The intermediate risk sample showed the highest chimerism levels in scaffolds coated with human 21 
MSCs compared to murine MSCs, and secondary engraftment was only observed with cells 22 
harvested from human scaffolds (Figure 4B). Finally, the favorable risk sample efficiently 23 
 13 
 
engrafted in the human scaffolds, and only at very late timepoints in the murine scaffolds (day 322) 1 
(Figure 4B). Efficient secondary transplantation was observed in all three cases in mice carrying 2 
scaffolds coated with human MSCs. No significant differences were seen in secondary 3 
transplantation of adverse risk sample #27 when scaffolds coated with human versus murine MSCs 4 
were compared, but significantly delayed secondary engraftment was observed with intermediate 5 
risk sample #18 in the scaffolds coated with murine MSCs. Failure of engraftment in the murine 6 
scaffolds was not due to insufficient formation of an extramedullary murine niche development 7 
(Figure 4D). 8 
 9 
Evaluation of clonal heterogeneity and clonal drift within humanized and murine niches. 10 
We selected three cases (#1, #2 and #3) in order to evaluate clonal heterogeneity and clonal drift. 11 
Variant allelic frequencies (VAF, exome seq) of recurrent mutations were determined in patient 12 
samples at presentation, and in tumor material harvested from the humanized scaffold niche, from 13 
the murine BM niche, and from in vitro expanded AML on MS5 bone marrow stromal cells 14 
supplemented with human cytokines. For #2 the CD34
+
 fraction of the patient, two huBM-sc 15 
samples, one muBM sample and in vitro expanded sample could be analyzed. As shown in Figure 16 
5A, a number of mutations were detected with approximately 50% VAF, including XBP1, APC, 17 
RPTOR, FLNC and MLL2 mutations, which were detected at the start, in the huBM-sc samples as 18 
well as in the in vitro expanded  sample. In all these cases, the inv16 and t(9;22) translocation were 19 
detected as well (data not shown). In contrast, these mutations were not detected in the muBM 20 
expanded sample, which had lost the inv16, t(9;22) and mutations indicated above, but instead 21 
displayed IDH1 mutations with an VAF of 50% which was only detected at low percentage in the 22 
diagnostics sample, and various other mutations that had remained below the detection limit in the 23 
 14 
 
diagnostic sample (Figure 5A), clearly indicating a change in clonal composition in the absence of 1 
a humanized microenviroment. For AML #1 this clonal drift was not seen, although a small clone 2 
or clones appeared with mutations in e.g. BCOR, KDM6A, PTPN11 and APC in the muBM that 3 
was not detected at diagnosis or in the huBM-sc samples, while at day 43 in the in vitro expanded 4 
cells again a different clone(s) appeared with mutations in HDAC7, IKZF1, MLL and XBP1 5 
(Figure 5B). In sample #3 the main clone(s) with approximately 50% VAF in NRAS, MSH6, 6 
DNMT3A was present at diagnosis and in the huBM-sc as well as the muBM samples. The 7 
diagnosis sample also contained mutations in MUTYH and PLCG2 with a VAF of approximately 8 
50% that was also seen in the huBM-sc sample but only at a very low VAF in the muBM sample 9 
suggesting that this was an independent clones that did not efficiently grow out in the murine 10 
niche. Finally, new small clone(s) appeared as well with low VAF in both the huBM-sc and muBM 11 
samples that were not detected in the diagnostic sample (Figure 5C). Together, these data clearly 12 
indicate that clonal heterogeneity and clonal drift are important parameters to evaluate in in vitro 13 
and in vivo models, and that a humanized niche might be better suited to maintain clonal 14 
heterogeneity observed at diagnosis. 15 
 16 
Human MSCs are better in supporting long-term expansion of human AML compared to 17 
murine bone marrow stroma. 18 
In vitro experiments were performed using either human MSCs, murine MS5 bone marrow stromal 19 
cells or liquid culture without stroma using #2 and #1 as representative examples. In all cases, 20 
CD34
+
-sorted AML cells were grown with or without a cocktail of human cytokines IL3, G-CSF 21 
and TPO as we previously described.
21-23
 No long-term cultures could be established without 22 
stroma, although some expansion was observed for #2 in liquid-culture conditions with cytokines, 23 
 15 
 
but within 20 days cells differentiated and stopped expanding (Supplemental Figure 5A). Human 1 
MSCs clearly were superior in supporting long-term expansion of both AML samples even in the 2 
absence of additional cytokines (Supplemental Figure 5A). The addition of cytokines did further 3 
enhance expansion in both murine MS5 as well as in human MSC cocultures, but the immature 4 
CD117
+
 phenotype was clearly better preserved in the absence of cytokines, in particular for AML 5 
#2 and to a lesser degree for AML #1 (Supplemental Figure 5B-C). 6 
 7 
Stemness transcriptome signatures are better preserved in a humanized niche. 8 
Transcriptome studies were performed on diagnostic samples as well as on huBM-sc and muBM 9 
derived samples from leukemic mice for 6 patient samples (Supplemental Table 3). Unsupervised 10 
hierarchical cluster analysis revealed that each patient displayed a unique transcriptome signature 11 
regardless of where cells were retrieved from (huBM-sc, muBM or diagnostic sample) (Figure 6A). 12 
Supervised clustering within individual patient samples revealed that diagnostic samples clustered 13 
most closely together with the huBM-sc samples for AML cases #2, #3, #6 and #4 (Figure 6B). 14 
This was not the case for AML #1 for which we had indeed already observed that this sample was 15 
less dependent on a human environment for its self-renewal and stemness properties, and also for 16 
the B-ALL sample #5 (Figure 6B). Gene Ontology (GO) analyses revealed that specific gene sets 17 
were differently regulated in the human versus murine niche, including processes such as 18 
transcription regulation, immune response, inflammatory response, mitochondria, and regulation of 19 
apoptosis (Figure 6C). In line with our secondary transplantation studies, GSEA analyses revealed 20 
significant enrichment for Leukemic Stem Cell signatures for #2 and #3 when grown in the 21 
humanized scaffold compared to the murine BM, while this was not observed for sample #1 22 
(Figure 6D). Instead, a significant enrichment for leukemic-GMP signatures was observed (Figure 23 
 16 
 
6D). Examples of gene expression of individual genes are shown in Figure 6E, indicating that 1 
expression of stem cell-related genes such as BMI1, HOXA5, HOXA9, CD34, CDKN1C and 2 
GATA2 was better preserved in the human niche compared to the murine niche for AML #2, while 3 
this was much less explicit for AML #1. 4 
 5 
 6 
Discussion 7 
Hematopoietic stem cells, and the same holds true for leukemic stem cells, do not simply live 8 
alone.  They are surrounded by a variety of other cell types that together constitute the stem cell 9 
niche in the bone marrow.
24-28
 In order to begin to understand mechanisms that regulate self-10 
renewal, differentiation and transformation of human hematopoietic stem cells, both intrinsic 11 
mechanisms as well as extrinsic mechanisms involving cues from the environment need to be taken 12 
into account.
29,30
   Even though the currently available immune deficient NSG xenograft mouse 13 
models are considered the gold standard for evaluating engraftment of human haematological 14 
malignancies, these models have serious drawbacks since only a limited percentage of primary 15 
AML patient samples can engraft and these models are strongly lymphoid biased.
1-8
 Clearly, a 16 
human bone marrow microenvironment that would provide a suitable home for normal and 17 
leukemic stem cells is lacking in these animals. To capture and maintain stem cell self-renewal 18 
programs and clonal heterogeneity as is observed in patients, a human niche appears to be essential. 19 
By making use of scaffolds coated with human MSCs to create a humanized environment in mice 20 
we have established human xenograft mouse leukemia models that can serve as a resource for 21 
leukemic stem cell studies and the evaluation of novel therapeutic approaches. We find that by 22 
providing a humanized environment: i) 29 out of 39 (74%) leukemia cases could efficiently engraft 23 
in the huBM-sc model covering all important genetic subtypes and risk groups, whereby also all 24 
 17 
 
favorable risk inv(16) patient samples could engraft, which are notoriously difficult to engraft in 1 
NSG mice; ii) stem cell self-renewal is better preserved in essentially all investigated cases in the 2 
huBM-sc as compared to the mouse bone marrow niche as determined by serial transplantation 3 
assays; iii) clonal heterogeneity as observed in the original patient is much better preserved in the 4 
huBM-sc compared to the mouse BM, at least in one case; and iv) stem cell self-renewal signatures 5 
are better preserved in the huBM-sc in the majority of cases. Even when cells were injected i.v. in 6 
mice carrying human scaffolds, better engraftment was observed in all 5 studied cases, whereby in 7 
3/5 cases no or hardly any engraftment was observed at all in the mouse bone marrow 8 
compartment. When scaffolds were coated with mouse MSCs instead of human MSCs, a favorable 9 
risk sample failed to engraft, and an intermediate risk sample engrafted less efficiently in primary 10 
mice, and not at all in secondary mice. During the course of our studies, Reinisch et al also 11 
described that ossicles generated by injecting human MSCs with matrigel in xenograft mice could 12 
generate a humanized niche in which leukamia patient samples could engraft more efficiently, 13 
including favorable risk PML-RARa samples that are notoriously difficult to engraft in normal 14 
NSG mice.
31
 These data are nicely in line with ours providing independent confirmation of the 15 
robustness of these humanized niche xenograft mouse models, but we also provide evidence that 16 
stem cell self-renewal is better preserved in a humanized niche as determined by transcriptome 17 
studies and serial transplantations.  18 
Obviously, heterogeneity exists between leukemia patients, and we find that some patient samples 19 
are more dependent on the presence of a human niche than others. As examples, we extensively 20 
studied 2 cases: AML #2 which strongly depended on a humanized environment, and AML #1 for 21 
which this was much less the case. Consistently, AML #2 could not engraft when i.v.-injected in 22 
mice without human scaffolds, the original patient phenotype defined by flow and transcriptome 23 
 18 
 
signatures defined by genome-wide transcriptome studies was better maintained in the human 1 
scaffolds, self-renewal properties were better preserved in the human scaffolds, and finally the 2 
dominant BCR-ABL/inv(16) clone that was present in the original patient sample also grew out in 3 
humanized scaffolds while in the mouse bone marrow this clone was absent and instead an minor 4 
clone carrying e.g. an IDH1 mutation expanded. Similar observations were published by others
32
, 5 
showing that upon transplantation of AML samples in NSG or even NSG-SGM3 mice clonal drift 6 
can occur, stressing the need for careful genomic analysis of engrafted clones. At the other end of 7 
the spectrum, AML #1 could also engraft when injected i.v. into mice without human scaffolds, the 8 
original patient phenotype defined by flow and transcriptome signatures was more comparable 9 
between human and murine niches, and secondary engraftment could be achieved with muBM-10 
harvested cells as well, albeit with lower frequencies as compared to huBM scaffold-retrieved cells.  11 
Overall, our data indicate that the humanized scaffold models will serve as an excellent resource 12 
for future studies aimed at exploring novel therapeutic approaches. Experiments were carried out 13 
independently in 2 institutes using 2 different mouse strains, NSG and RAG2
-/-c-/- mice, showing 14 
the robustness of the model. Clinical trials often fail when evaluating drugs that appeared 15 
successful in in vitro and in vivo studies
33,34
, and in part this might be related to the models used, 16 
whereby a humanized environment was not included. Finally, the current model allows for an 17 
efficient evaluation of drug efficacy as well, as already documented for multiple myeloma 
18
 and 18 
MLL-AF9 models
35
, indicating that the human leukemia xenograft mouse models that we have 19 
established here will serve as an excellent resource for future studies aimed at exploring novel 20 
therapeutic approaches. 21 
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Figures Legends 26 
 27 
Figure 1. Overview of the mouse xenograft leukemia models. A, Schematic representation of 28 
the generation of muBM-iv and huBM-sc models. B, Representative HE stain of scaffold sections 6 29 
weeks after implantation; b, bone; s, scaffold; v, blood vessels. C, Success rate of leukemia 30 
development in muBM-iv and huBM-sc models, expressed as percentage of AML samples from 31 
 23 
 
different risk groups, which engrafted or not in the two xenograft models. D, Scatter plots showing 1 
engraftment of donor human CD45
+ 
cells in different compartments of the mouse at sacrifice 2 
(huBM-sc, humanized scaffolds; muBM, murine bone marrow; muSp, murine spleen; muLv, 3 
murine liver; muPB, murine peripheral blood). Engraftment values from several mice for each 4 
AML sample are expressed as mean±SEM. Route 1: cells were directly injected into the humanized 5 
scaffolds, route 2: cells were injected i.v. in mice without humanized scaffolds. E, Experiment as in 6 
(d), but now cells were injected i.v. in mice carrying humanized scaffolds. F, In vivo tumor growth 7 
rates of the biggest tumor scaffold of each mice. Each colored line represents one mouse from a 8 
certain AML sample. Tumor size (cm
3
) was used as endpoint of the experimental period.  9 
 10 
Figure 2. Mouse xenograft AML model using sample AML #2. A, FACS immunophenotype of 11 
AML #2 patient-derived MNCs cells. B, Representative photograph depicting the “leukemic 12 
masses” formed around the extramedullary bones of Sc1 and Sc3 and two scaffolds with no tumor 13 
growth (Sc4, not injected control scaffold), at mouse sacrifice. C, Representative FACS phenotype 14 
from a primary huBM-sc mouse (m23, see Table S1) transplanted with AML #2 cells. Expression 15 
of a panel of hematopoietic markers in huCD45
+
 gated cells isolated from different scaffolds or 16 
from the murine BM. D, Bar graph summarizing the FACS phenotype of human CD45
+
 cells from 17 
different compartments of all mice injected with #2 AML cells, compared with original patient 18 
phenotype. Values are expressed as mean±SEM. E, Histologic sections of scaffold tumor from a 19 
representative #2 huBM-sc mouse (m24, Sc1) stained with HE, anti-huCD45 or anti-huCD33 20 
antibodies. F, Representative images (m23) of May Grünwald Giemsa (MGG)-stained 21 
cytospins of  cells retrieved from Sc1, Sc3 or BM.  22 
 23 
 24 
 
Figure 3. Assessment of the self-renewal potential of engrafting AML cells by serial 1 
transplantation of three AML samples. A, Setup of secondary transplantation experiments. 2 
HuCD45
+ 
cells harvested from from a scaffold or from the BM of primary huBM-sc mice were 3 
injected in the scaffolds of secondary recipient NSG mice implanted with the humanized niches 6-8 4 
weeks before the transplantation of leukemic cells. B,D,F, Representative FACS analysis of 5 
secondary recipient mice of AML #2, AML #3 and AML #1, respectively. C,E,G, In vivo tumor 6 
growth rates of the biggest tumor scaffold in secondary transplanted mice from AML #2, AML #3 7 
and AML #1, respectively . Each colored line represents one mouse and the cell dosage and source 8 
(SC=human scaffold or BM=mouse bone marrow) are depicted in the corresponding legend. 9 
Tumor size (cm
3
) was used as endpoint of the experimental period.  10 
 11 
Figure 4. Assessment of the self-renewal potential of engrafting AML cells by serial 12 
transplantation of three AML samples. A, Schematic representation of the generation of mouse 13 
models with scaffolds coated with human MSCs (huBM-sc) versus murine MSCs (muBM-sc). B, 14 
Plots showing % engraftment of donor human CD45
+ 
cells in the scaffolds in huBM-sc versus 15 
muBM-sc models, using patient samples with adverse, intermediate and favorable risk. 16 
Engraftment values from 8 scaffolds in 2 mice (mouse 1 indicated with red symbols and mouse 2 17 
indicated with black symbols) for each AML sample are expressed as mean±SEM. C, For 18 
secondary transplantations, leukemic
 
cells harvested from the scaffold of a primary huBM-sc or 19 
muBM-sc mouse were injected in the scaffolds of secondary recipient huBM-sc or muBM-sc mice. 20 
Kaplan Meijer plots are shown. Significant better secondary engraftment for the intermediate risk 21 
sample #18 was shown in the huBM-sc model, while significant better engraftment for the 22 
favorable risk sample (#33) was already observed in the primary transplantations. D, Ceramic 23 
 25 
 
scaffold implants coated with murine MSCs generate an ectopic hematopoietic niche.  HE stains of 1 
different murine implants, before inocculation with AML. As shown the scaffolds (s) are covered 2 
by murine bone (b) with vascularization (v), resulting in the support of the murine hematopoiesis in 3 
Rag2-/-γc-/- mice. 4 
 5 
Figure 5. In vivo and in vitro maintenance of the genetic heterogeneity of the original AML 6 
patient samples. Exome sequencing to determine variant allele frequency in the leukemic 7 
populations for 3 representative AML samples: A, #2, B, #1, C, #3. Vertical axis shows the 8 
percentage of variant reads per allele, corresponding to different somatic mutations indicated in the 9 
legend. On the horizontal axis, several samples from same AML are depicted. All samples were 10 
sorted for huCD45 expression before sequencing. VAF around 50% indicated clonal mutations 11 
with heterozygous configuration. VAF around 100% would indicate clonal mutations with 12 
homozigous configuration, whilst frequencies lower than 50% show the presence of subclonal 13 
mutations. 14 
 15 
Figure 6. Gene expression profiling of patient derived-AML cells and engrafted in the 16 
humanized or murine hematopoietic niche of huBM-sc mice. A, Unsupervised hierarchical 17 
cluster analysis (Pearson uncentered absolute distance, average linkage)  on gene expression 18 
profiles of muBM- or huSC-engrafted huCD45
+
 cells or patient- derived (MNCs or CD34
+
) 19 
leukemic cells from six different AMLs.  B, Supervised cluster with Euclidean distance and ward 20 
linkage analyses per AML using genes that were differentially expressed between huBM-sc and 21 
muBM-retrieved cells (fold change (FC) ≥ 3). C, GO analyses on genes that were differentially 22 
expressed between huBM-sc and muBM-retrieved cells (fold change (FC) ≥ 3). D, GSEA analyses 23 
 26 
 
on genes that were differentially expressed between huBM-sc and muBM-retrieved cells (fold 1 
change (FC) ≥ 3). E, Expression of individual stem cell-related genes in the diagnostic patient 2 
sample and huBM-sc and muBM-retrieved cells. 3 
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